



July 27, 2012

Company name: Dainippon Sumitomo Pharma Co., Ltd.

Representative: Masayo Tada, President

(Securities Codes: 4506, 1st Section of TSE and OSE)

Contact: Atsuko Higuchi, Director, Corporate Communications

(Phone: +81-6-6203-1407)

Revision of Financial Forecasts

In light of recent performance trends and other factors, Dainippon Sumitomo Pharma Co., Ltd. announces revisions to the financial forecasts made on May 10, 2012.

(Millions of yen)

1. Revision of Consolidated Financial Forecasts for the Second Quarter of the Year Ending March 31, 2013 (April 1, 2012 to September 30, 2012)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
Previous Forecasts (A)	176,000	11,000	10,500	5,000	¥12.58
New Forecasts (B)	179,000	17,200	17,000	8,800	¥22.15
(B) – (A)	3,000	6,200	6,500	3,800	
Change (%)	1.7	56.4	61.9	76.0	
(Reference) Results for Second Quarter of the year ended March 31, 2012	178,026	14,726	14,480	9,569	¥24.09

2. Revision of Consolidated Financial Forecasts for the Year Ending March 31, 2013 (April 1, 2012 to March 31, 2013)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
Previous Forecasts (A)	348,000	22,000	21,000	10,500	¥26.43
New Forecasts (B)	348,000	25,000	24,000	12,000	¥30.20
(B) – (A)	–	3,000	3,000	1,500	
Change (%)	–	13.6	14.3	14.3	
(Reference) Results for the year ended March 31, 2012	350,395	20,402	18,872	8,629	¥21.72

3. Reason for revision

(1) Second Quarter of the Year Ending March 31, 2013

Due to strong sales from existing products in North America, a divergence in the time of product shipment in China, etc., net sales are expected to exceed the previous forecasts. On the other hand, in addition to the impact of the yen's appreciation, marketing costs for new products in North America being shifted to the third quarter, etc., SG&A expenses are expected to be lower than the previous forecasts.

Consequently, in the revised consolidated financial forecasts for the first half of the year ending March 31 2013, net sales increase by 3.0 billion yen to 179.0 billion yen, operating income increases by 6.2 billion yen to 17.2 billion yen, ordinary income increases by 6.5 billion yen to 17.0 billion yen and net income increases by 3.8 billion yen to 8.8 billion yen compared to the previous forecasts on May 10, 2012.

(2) Year Ending March 31, 2013

Although for North America there is an impact from currency exchange, strong sales are expected to continue from existing products. On the other hand, with the increased impact from generic drug utilization promoted in Japan, the Company expects no change to the previous forecasts for total net sales.

For SG&A expenses excluding R&D, from the third quarter, operating expenses in North America are expected to increase. However, because of the appreciation of the yen, etc., the forecasts remain unchanged. For reasons including the yen's appreciation, etc., R&D expenses are expected to decrease compared to the previous forecasts.

Consequently, in the revised consolidated financial forecasts for the year ending March 31 2013, the Company anticipates that operating income increases by 3.0 billion yen to 25.0 billion yen, ordinary income increases by 3.0 billion yen to 24.0 billion yen and net income increases by 1.5 billion yen to 12.0 billion yen compared to the previous forecasts on May 10, 2012.

In addition, in light of recent currency movements, the forecast exchange rate for the year Ending March 31, 2013 has been changed to 80yen/US\$1 (previously 83yen/US\$1).

Note: Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involves risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.